ONTRUZANT® (trastuzumab-dttb) for Injection, for Intravenous Use 21 mg/ml

Please read the Prescribing Information for ONTRUZANT, including the
information about heart problems, infusion reactions (lung problems),
and harm to an unborn baby, and discuss it with your doctor.


SUPPORT RESOURCES

RESOURCE
Electronic Enrollment

The Organon Access Program 2022 Electronic Patient Enrollment Form

This patient form can be signed and submitted electronically. Please note that your health care provider must also submit the Health Care Provider Enrollment Form.

The Organon Access Program 2023 Electronic Patient Enrollment Form

This patient form can be signed and submitted electronically. Please note that your health care provider must also submit the Health Care Provider Enrollment Form. Use this form to re-enroll for 2023.

Enrollment

The Organon Access Program 2022 Enrollment Form

The Organon Access Program 2023 Enrollment Form

Use this form to re-enroll for 2023.

The Organon Access Program 2023 Sample Enrollment Form

Representative's Form

Potential Independent Foundation Support

Patient Support Materials

ONTRUZANT.com

Product Information

Physician Prescribing Information



 WELCOME TO

Welcome to The Organon Access Program for ONTRUZANT® (trastuzumab-dttb)

ARE YOU A US HEALTH CARE PROFESSIONAL?

Please choose